Fig. 2.

Most prevalent drug-resistant mutations for each analysis group by drug class, Washington DC, 1999–2014. NRTI, nucleoside/nucleotide analogue reverse transcriptase inhibitor (top 4); NNRTI, nonnucleoside reverse transcriptase inhibitor (top 4); PI, protease inhibitor (top 4); EI, entry/fusion inhibitor (top 2); INSTI, integrase strand transfer inhibitor (top 2)